Supplement encyclopedia

METHOSULFONYLMETHANE

Methylsulfonylmethane (MSM), also called dimethyl sulfone, is a sulfur-containing compound found in dietary supplements.

Double-check the conclusions and read the sources before choosing a supplement.

Main conclusion

What it may offer

  • For mild knee discomfort, 2 g MSM daily may slightly ease complaints: after 12 weeks, the overall symptom score was lower than with placebo.
  • In knee osteoarthritis, 6 g MSM daily over 12 weeks reduced pain and limitations in everyday movement more than placebo.
  • In another knee-osteoarthritis study, 3.375 g MSM daily over 12 weeks improved function and overall symptoms, but separate pain and stiffness scores did not differ convincingly from placebo.
  • Taking 3 g MSM daily before and after a half-marathon showed no convincing advantage over placebo in reducing muscle pain.
  • MSM may make wrinkles less noticeable: in a small study of women aged 35–59, expert wrinkle ratings after 16 weeks at 3 g daily were lower than with placebo.

[1] [2] [3] [4] [5]

What was studied

  • Three knee studies separately assessed mild discomfort and symptoms in people with knee osteoarthritis.
  • Two other small studies measured muscle pain after a half-marathon and assessed facial wrinkle visibility.

[1] [2] [3] [4] [5]

Which forms were considered

  • These trials studied MSM alone taken orally.
  • When choosing a formulation, distinguish MSM, dimethyl sulfoxide and mixtures: these results concern oral MSM alone.

[1] [2] [3] [4] [5] [6]

How to get it from food

  • Small amounts of MSM can come from fruit, vegetables and grains—its plant food sources.
  • MSM also occurs in meat, eggs and fish, so animal foods provide sources too.

[1]

Effects and studied questions

How to read the certainty scale 1–4

Certainty is rated separately for each outcome. 1 is very low, 2 is low, 3 is moderate and 4 is high.

Goal or questionResultConfidenceStudiesPopulation studiedKey sources
Total JKOM knee-complaint scoreIn the 80 analyzed adults with mild knee symptoms, after 12 weeks at 2 g MSM daily, total JKOM was 8.1 versus 10.9 on placebo; fewer points mean fewer complaints.Final JKOM 8.1 versus 10.9; difference −2.8 (95% CI −5.5…−0.1), p=0.046
2/4 LowConfidence is low: in a blinded study of people with mild knee complaints, some participants were excluded from the analysis after group allocation. The difference in final scores is small and its confidence interval permits both an almost zero and a more noticeable difference; its importance for well-being has not been established.
11 trialMethylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗Japanese adults with mild knee discomfort, Kellgren–Lawrence 0–1; 88 randomized, 80 analyzed
  1. Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
General condition on the JKOM subscaleIn the same study, the JKOM general-condition measure changed by −1.3 points with MSM and −0.9 with placebo; difference in changes −0.5 points (95% CI −0.9…−0.0).Change −1.3 versus −0.9; difference −0.5 (95% CI −0.9…−0.0), p=0.032
2/4 LowConfidence is low: some participants were excluded from the analysis after group allocation. The difference in change in the general health measure is small and the interval is close to zero; the available description does not allow a confident judgment of its importance to a person.
11 trialMethylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗Japanese adults with mild knee discomfort; 88 randomized, 80 analyzed
  1. Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗
Pain in knee osteoarthritisIn patients with knee osteoarthritis, 6 g MSM daily over 12 weeks reduced WOMAC pain by 14.6 mm versus 7.3 mm with placebo (p=0.041).WOMAC pain change −14.6 versus −7.3 mm on a 0–100 scale; p=0.041
Not assessedConfidence in the stated magnitude of pain reduction cannot be assessed: the available abstract reports improvement relative to placebo, but does not allow verification that −14.6 and −7.3 mm are changes over 12 weeks in the two groups, or assessment of the precision of this comparison.
11 trialEfficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗Adults with knee osteoarthritis; 50 randomized, 40 completed (21 MSM, 19 placebo)
  1. Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗

The study count refers to the cited source. Reviews with overlapping trials and outcomes from one study are not added together.

Forms

MSM is methylsulfonylmethane (dimethyl sulfone), a distinct oral compound; results for DMSO, creams and mixtures do not apply to it.

Guidance for each goal

Total JKOM knee-complaint score2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: in a blinded study of people with mild knee complaints, some participants were excluded from the analysis after group allocation. The difference in final scores is small and its confidence interval permits both an almost zero and a more noticeable difference; its importance for well-being has not been established.

In the 80 analyzed adults with mild knee symptoms, after 12 weeks at 2 g MSM daily, total JKOM was 8.1 versus 10.9 on placebo; fewer points mean fewer complaints.

Study findings. In the 80 analyzed adults with mild knee symptoms, after 12 weeks at 2 g MSM daily, total JKOM was 8.1 versus 10.9 on placebo; fewer points mean fewer complaints.

Studied regimen2 g/dayOral MSM alone
Duration and population12 weeksJapanese adults with mild knee discomfort, Kellgren–Lawrence 0–1; 88 randomized, 80 analyzed

Comparison: Placebo

General condition on the JKOM subscale2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: some participants were excluded from the analysis after group allocation. The difference in change in the general health measure is small and the interval is close to zero; the available description does not allow a confident judgment of its importance to a person.

In the same study, the JKOM general-condition measure changed by −1.3 points with MSM and −0.9 with placebo; difference in changes −0.5 points (95% CI −0.9…−0.0).

Study findings. In the same study, the JKOM general-condition measure changed by −1.3 points with MSM and −0.9 with placebo; difference in changes −0.5 points (95% CI −0.9…−0.0).

Studied regimen2 g/dayOral MSM alone
Duration and population12 weeksJapanese adults with mild knee discomfort; 88 randomized, 80 analyzed

Comparison: Placebo

Pain in knee osteoarthritisNot assessedRead moreCollapse
Confidence
Not assessedConfidence in the stated magnitude of pain reduction cannot be assessed: the available abstract reports improvement relative to placebo, but does not allow verification that −14.6 and −7.3 mm are changes over 12 weeks in the two groups, or assessment of the precision of this comparison.

In patients with knee osteoarthritis, 6 g MSM daily over 12 weeks reduced WOMAC pain by 14.6 mm versus 7.3 mm with placebo (p=0.041).

Study findings. In patients with knee osteoarthritis, 6 g MSM daily over 12 weeks reduced WOMAC pain by 14.6 mm versus 7.3 mm with placebo (p=0.041).

Studied regimen6 g/dayOral MSM alone
Duration and population12 weeksAdults with knee osteoarthritis; 50 randomized, 40 completed (21 MSM, 19 placebo)

Comparison: Placebo

Knee function in osteoarthritisNot assessedRead moreCollapse
Confidence
Not assessedConfidence in the stated magnitude of reduction in knee function impairment cannot be assessed: the available abstract reports improvement relative to placebo, but does not allow verification that −15.7 and −8.8 mm are changes over 12 weeks in the two groups, or assessment of the precision of this comparison.

In the same trial, WOMAC knee-function impairment fell by 15.7 mm with MSM and 8.8 mm with placebo (p=0.045).

Study findings. In the same trial, WOMAC knee-function impairment fell by 15.7 mm with MSM and 8.8 mm with placebo (p=0.045).

Studied regimen6 g/dayOral MSM alone
Duration and population12 weeksAdults with knee osteoarthritis; 50 randomized, 40 completed

Comparison: Placebo

WOMAC knee function2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: participants were allocated in order of arrival, so allocation could have been predictable. The small study leaves a wide range of possible improvement; the reported interval and p-value come from different analyses.

In patients with confirmed knee osteoarthritis, 3.375 g MSM daily over 12 weeks improved WOMAC function by 14.6 mm versus placebo (95% CI 4.3–25.0).

Study findings. In patients with confirmed knee osteoarthritis, 3.375 g MSM daily over 12 weeks improved WOMAC function by 14.6 mm versus placebo (95% CI 4.3–25.0).

Studied regimen1.125 g 3 times/day, total 3.375 g/dayOral MSM alone
Duration and population12 weeksPatients aged 45–90 with clinically and radiographically confirmed knee osteoarthritis; 50 randomized

Comparison: Placebo

Total WOMAC score2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: the order of participant allocation may have been predictable, and the small study does not allow the size of improvement to be determined precisely. The reported interval and p-value were obtained in different analyses.

In the same trial, total WOMAC improved by 15.0 mm versus placebo (95% CI 5.1–24.9) over 12 weeks.

Study findings. In the same trial, total WOMAC improved by 15.0 mm versus placebo (95% CI 5.1–24.9) over 12 weeks.

Studied regimen3.375 g/dayOral MSM alone
Duration and population12 weeksPatients aged 45–90 with confirmed knee osteoarthritis; 50 randomized

Comparison: Placebo

WOMAC pain and stiffness2/4 LowRead moreCollapse
Confidence
2/4 LowConfidence is low: participants were allocated in order of arrival, which may have affected group composition. Estimates for pain and stiffness are imprecise; the intervals and p-values come from different analyses and cannot therefore be interpreted as a single result.

In the same study, separate WOMAC pain and stiffness subscales showed no convincing difference from placebo: both p=0.08.

Study findings. In the same study, separate WOMAC pain and stiffness subscales showed no convincing difference from placebo: both p=0.08.

Studied regimen3.375 g/dayOral MSM alone
Duration and population12 weeksPatients aged 45–90 with confirmed knee osteoarthritis; 50 randomized

Comparison: Placebo

Muscle pain after a half-marathon3/4 ModerateRead moreCollapse
Confidence
3/4 ModerateConfidence is moderate: the blinded study included few runners, and the confidence interval for pain at 15 minutes permits both a substantial reduction and a small increase in pain. The article has an inconsistency in group sizes; a non-significant overall interaction alone does not prove absence of an effect.

Among 21 half-marathon participants with completed pain ratings, the time course of muscle pain on 3 g MSM daily did not differ convincingly from placebo; at 15 minutes the difference was −19.8 mm (95% CI −43.7…+4.1).

Study findings. Among 21 half-marathon participants with completed pain ratings, the time course of muscle pain on 3 g MSM daily did not differ convincingly from placebo; at 15 minutes the difference was −19.8 mm (95% CI −43.7…+4.1).

Studied regimen3 g/dayOral MSM alone
Duration and population21 days before the race and 2 days after22 randomized; 21 assessed muscle pain (11 MSM, 10 placebo)

Comparison: Placebo

Facial wrinkle visibilityNot assessedRead moreCollapse
Confidence
Not assessedThe certainty of the wrinkle result cannot yet be assessed: the available abstract does not describe the allocation method or expert blinding, and does not report the magnitude of the between-group difference. Therefore, it is unknown how much the result depends on features of the comparison and how large the possible effect is.

In a small trial of 20 women, facial wrinkle ratings after 16 weeks were lower with 3 g MSM daily than placebo (p<0.05); the article gives no exact between-group effect size.

Study findings. In a small trial of 20 women, facial wrinkle ratings after 16 weeks were lower with 3 g MSM daily than placebo (p<0.05); the article gives no exact between-group effect size.

Studied regimen3 g/dayOral MSM alone
Duration and population16 weeksWomen aged 35–59 with signs of skin aging; 20 completed (11 MSM, 9 placebo)

Comparison: Placebo

Safety and limitations

VKM considers that 3 g MSM daily from supplements may pose adverse-effect risk for adults aged 18 and over. VKM assessed 0.2 g daily as unlikely to cause harm in healthy adults of this age group; this is not a recommended dose. Insufficient data prevented VKM from establishing a safe daily dose for children and adolescents. Digestive symptoms, rash and allergic reactions are possible. Short studies found no serious problems, but data on long-term use, pregnancy, breastfeeding and drug interactions are limited; no reported cases does not establish safety of combinations. Knee-osteoarthritis clinical findings apply to people with that diagnosis and their symptoms; JKOM findings came separately from people with mild discomfort without marked radiographic osteoarthritis.

Risk assessment of methylsulfonylmethane in food supplements ↗ · Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗ · Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗ · Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study ↗ · Dimethyl Sulfoxide (DMSO) and Methylsulfonylmethane (MSM) for Osteoarthritis ↗

Food sources

Foods contain small amounts of MSM; food mass is not the MSM dose in a supplement.

Trace MSM occurs in various fruit, vegetables, grains, meat, eggs and fish; food amounts are not equivalent to gram doses in trials.

Risk assessment of methylsulfonylmethane in food supplements ↗

Fruit and vegetables Small amounts of MSM occur in various fruit and vegetables.

Risk assessment of methylsulfonylmethane in food supplements ↗

Grains Small amounts of MSM also occur in grains.

Risk assessment of methylsulfonylmethane in food supplements ↗

Studies

PublicationWhat was studiedParticipantsForm and doseResult
Methylsulfonylmethane Improves Knee Quality of Life in Participants with Mild Knee Pain: A Randomized, Double-Blind, Placebo-Controlled Trial ↗Total JKOM knee-complaint score: Total JKOM knee-complaint score General condition on the JKOM subscale: General condition on the JKOM subscaleTotal JKOM knee-complaint score: Japanese adults with mild knee discomfort, Kellgren–Lawrence 0–1; 88 randomized, 80 analyzed General condition on the JKOM subscale: Japanese adults with mild knee discomfort; 88 randomized, 80 analyzedTotal JKOM knee-complaint score: Oral MSM alone; 2 g/day; 12 weeks; comparison: Placebo General condition on the JKOM subscale: Oral MSM alone; 2 g/day; 12 weeks; comparison: PlaceboTotal JKOM knee-complaint score: In the 80 analyzed adults with mild knee symptoms, after 12 weeks at 2 g MSM daily, total JKOM was 8.1 versus 10.9 on placebo; fewer points mean fewer complaints. General condition on the JKOM subscale: In the same study, the JKOM general-condition measure changed by −1.3 points with MSM and −0.9 with placebo; difference in changes −0.5 points (95% CI −0.9…−0.0).
Efficacy of methylsulfonylmethane (MSM) in osteoarthritis pain of the knee: a pilot clinical trial ↗Pain in knee osteoarthritis: Pain in knee osteoarthritis Knee function in osteoarthritis: Knee function in osteoarthritisPain in knee osteoarthritis: Adults with knee osteoarthritis; 50 randomized, 40 completed (21 MSM, 19 placebo) Knee function in osteoarthritis: Adults with knee osteoarthritis; 50 randomized, 40 completedPain in knee osteoarthritis: Oral MSM alone; 6 g/day; 12 weeks; comparison: Placebo Knee function in osteoarthritis: Oral MSM alone; 6 g/day; 12 weeks; comparison: PlaceboPain in knee osteoarthritis: In patients with knee osteoarthritis, 6 g MSM daily over 12 weeks reduced WOMAC pain by 14.6 mm versus 7.3 mm with placebo (p=0.041). Knee function in osteoarthritis: In the same trial, WOMAC knee-function impairment fell by 15.7 mm with MSM and 8.8 mm with placebo (p=0.045).